GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (NAS:ALVOW) » Definitions » NonCurrent Deferred Liabilities

Alvotech (Alvotech) NonCurrent Deferred Liabilities : $90.52 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Alvotech NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Alvotech's non-current deferred liabilities for the quarter that ended in Mar. 2024 was $90.52 Mil.

Alvotech NonCurrent Deferred Liabilities Historical Data

The historical data trend for Alvotech's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech NonCurrent Deferred Liabilities Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
- 39.09 44.99 57.33 73.31

Alvotech Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.82 57.43 72.76 73.31 90.52

Alvotech NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Alvotech's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Alvotech (Alvotech) Business Description

Industry
Traded in Other Exchanges
Address
9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.